Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label dose-comparison study of CDA-II in low- or intermediate-1-risk myelodysplastic syndrome
ChiCTR-IPR-14005363Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cladribine in myelodysplastic syndrome (MDS) (3 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Rate of hematologic improvement. Started Jul 2014; status: recruiting.
02
Drugs
cladribine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR-IPR-14005363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005363.